Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12:557–69.

Article  CAS  PubMed  Google Scholar 

Nakamura M, Iwahashi M, Nakamori M, Ueda K, Matsuura I, Noguchi K, et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res. 2002;8:2742–9.

CAS  PubMed  Google Scholar 

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer. 2007;120:585–93.

Article  CAS  PubMed  Google Scholar 

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, et al. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Int J Oncol. 2008;32:459–66.

CAS  PubMed  Google Scholar 

Miyazawa M, Iwahashi M, Ojima T, Katsuda M, Nakamura M, Nakamori M, et al. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Cancer Lett. 2011;305:32–9.

Article  CAS  PubMed  Google Scholar 

Katsuda M, Miyazawa M, Ojima T, Katanuma A, Hakamada K, Sudo K, et al. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. Trials. 2019;20:242.

Article  PubMed  PubMed Central  Google Scholar 

Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother. 2012;61:827–38.

Article  CAS  PubMed  Google Scholar 

Choi KD, Vodyanik MA, Slukvin II. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. J Clin Investig. 2009;119:2818–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells. 2009;27:1021–31.

Article  CAS  PubMed  Google Scholar 

Senju S, Haruta M, Matsumura K, Matsunaga Y, Fukushima S, Ikeda T, et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther. 2011;18:874–83.

Article  CAS  PubMed  Google Scholar 

Silk KM, Silk JD, Ichiryu N, Davies TJ, Nolan KF, Leishman AJ, et al. Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. Gene Ther. 2012;19:1035–40.

Article  CAS  PubMed  Google Scholar 

Yanagimachi MD, Niwa A, Tanaka T, Honda-Ozaki F, Nishimoto S, Murata Y, et al. Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS One. 2013;8:e59243.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iwamoto H, Ojima T, Hayata K, Katsuda M, Miyazawa M, Iida T, et al. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs. Int J Cancer. 2014;134:332–41.

Article  PubMed  Google Scholar 

Kitadani J, Ojima T, Iwamoto H, Tabata H, Nakamori M, Nakamura M, et al. Cancer vaccine therapy using carcinoembryonic antigen - expressing dendritic cells generated from induced pluripotent stem cells. Sci Rep. 2018;8:4569.

Article  PubMed  PubMed Central  Google Scholar 

Maruoka S, Ojima T, Iwamoto H, Kitadani J, Tabata H, Tominaga S, et al. Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro. Sci Rep. 2022;12:3295.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190–8.

Article  CAS  PubMed  Google Scholar 

Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012;103:739–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shin SJ, Park S, Kim MH, Nam CM, Kim H, Choi YY, et al. Mesothelin expression is a predictive factor for peritoneal recurrence in curatively resected stage III gastric cancer. Oncologist. 2019;24:e1108–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6:133–46.

Article  CAS  PubMed  Google Scholar 

Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, et al. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Oncotarget. 2018;9:31448–58.

Article  PubMed  PubMed Central  Google Scholar 

Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res. 2005;11:6342–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hung CF, Tsai YC, He L, Wu TC. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther. 2007;14:921–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, et al. Phase I/II study of the mesothelin-targeted immunotoxin LMB-100 with Nab-paclitaxel for patients with advanced pancreatic adenocarcinoma. Clin Cancer Res. 2020;26:828–36.

Article  CAS  PubMed  Google Scholar 

Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ. 2013;20:21–30.

Article  CAS  PubMed  Google Scholar 

Rouard H, Klonjkowski B, Marquet J, Lahet C, Mercier S, Andrieu M, et al. Adenoviral transgene ubiquitination enhances mouse immunization and class I presentation by human dendritic cells. Hum Gene Ther. 2003;14:1319–32.

Article  CAS  PubMed  Google Scholar 

Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, Chiba T, et al. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting ‘self’-antigens expressed in melanoma/melanocyte. Gene Ther. 2005;12:1049–57.

Article  CAS  PubMed  Google Scholar 

Duan X, Hisaeda H, Shen J, Tu L, Imai T, Chou B, et al. The ubiquitin-proteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells. Int Immunol. 2006;18:679–87.

Article  CAS  PubMed  Google Scholar 

Eslami NS, Shokrgozar MA, Mousavi A, Azadmanesh K, Nomani A, Apostolopoulos V, et al. Simultaneous immunisation with a Wilms’ tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Mol Immunol. 2012;51:325–31.

Article  CAS  PubMed  Google Scholar 

Bontkes HJ, Kramer D, Ruizendaal JJ, Kueter EW, van Tendeloo VF, Meijer CJ, et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 2007;14:366–75.

Article  CAS  PubMed  Google Scholar 

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297–306.

Article  CAS  PubMed  PubMed Central  Google Scholar